is a current employee at Vanderbilt University Medical Center. Email:
is Professor of Anesthesiology, retired from the Department of Anesthesiology and Perioperative Medicine at the University of Pittsburgh and is a past Director of the North American MH Registry of MHAUS.
AANA J. 2022 Aug;90(4):271-277.
Intravenous dantrolene is the first-line treatment of malignant hyperthermia (MH), however, it is not always accessible in lower-middle income countries (LMICs). Facilities in the United States are in a transition period where dantrolene is being replaced with Ryanodex, therefore, there is an opportunity for excess dantrolene to be utilized in LMICs where neither dantrolene nor Ryanodex exist. Thirty-six vials of recently expired, unused dantrolene were obtained for a hospital in a LMIC and an MH program was developed in conjunction with the Lao Friends Hospital for Children (LFHC) anesthesia providers, LFHC liaison, LFHC leadership team, and an expert in the field of MH. Components of the MH program included developing a facility-specific protocol, treatment guidelines, supply list, and educational tools. A designated MH drawer was also created in preparation for an MH event. By procuring dantrolene and implementing an MH program in a facility where no MH protocol, treatment guidelines, supply list, or educational tools existed, LFHC is better equipped to handle a potentially lethal scenario.
静脉注射丹曲林是治疗恶性高热（MH）的一线药物，但在中低收入国家（LMIC）并不总是能获得。美国的医疗机构正处于丹曲林被 Ryanodex 替代的过渡阶段，因此，在既没有丹曲林也没有 Ryanodex 的 LMIC 国家，有机会利用多余的丹曲林。为一家 LMIC 的医院获得了 36 瓶最近过期但未使用的丹曲林，与老挝儿童友谊医院（LFHC）的麻醉提供者、LFHC 联络人、LFHC 领导团队以及 MH 领域的专家一起制定了 MH 方案。MH 方案的组成部分包括制定特定于机构的方案、治疗指南、供应清单和教育工具。还创建了一个指定的 MH 抽屉，以备 MH 事件发生。通过采购丹曲林并在没有 MH 方案、治疗指南、供应清单或教育工具的机构中实施 MH 方案，LFHC 更有能力应对潜在的致命情况。
